- BioMarin Pharmaceutical (NASDAQ:BMRN) Q4 results ($M): Total Revenues: 300.1 (31.7%); Vimizim sales: 94 (+59.3%); Kuvan sales: 90 (+38.5%); Naglazyme sales: 75 (+25.0%); Aldurazyme sales: 35 (-10.3%).
- Net Loss: (90.7) (-232.2%); Non-GAAP Loss: (27) (+61.4%); Loss/Share: (0.53) (-235.9%).
-
2017 Guidance: Total Revenues: $1.25B - 1.30B; Kuvan sales: $380M - 410M; Naglazyme sales: $300M - 330M; Vimizim sales: $400M - 430M; Net Loss: ($140M - 180M); Non-GAAP Net Income: $30M - 70M.
- Share are unchanged after hours.